LivaNova (LIVN) and The Competition Head to Head Survey

LivaNova (NASDAQ:LIVN) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare LivaNova to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Institutional and Insider Ownership

97.6% of LivaNova shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LivaNova and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0	3	9	0	2.75
LivaNova Competitors	4281	10557	18338	829	2.46

LivaNova presently has a consensus target price of $101.22, indicating a potential upside of 9.74%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.32%. Given LivaNova’s rivals higher probable upside, analysts clearly believe LivaNova has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares LivaNova and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LivaNova	$1.39 billion	-$242.47 million	30.75
LivaNova Competitors	$1.89 billion	$135.83 million	12.27

LivaNova’s rivals have higher revenue and earnings than LivaNova. LivaNova is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares LivaNova and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LivaNova	13.01%	16.10%	7.85%
LivaNova Competitors	-304.51%	-178.77%	-22.17%

Risk and Volatility

LivaNova has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, LivaNova’s rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Summary

LivaNova beats its rivals on 7 of the 13 factors compared.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.